The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a comprehensive manuscript, “Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols” in the Journal for ImmunoTherapy of Cancer (JITC).
This work provides an in-depth examination of evidence-based biomarkers that measure the potential for therapeutic response and/or toxicity that are critical to guide optimal patient care and contextualize the results of immunotherapy clinical trials. Responding to the lack of guidance on biomarker testing in early phase immunotherapy clinical trials, SITC proposes a definition and listing of essential biomarkers recommended for inclusion in all such protocols. These recommendations are based on consensus provided by the SITC Clinical Immuno-Oncology Network (SCION) faculty with input from the SITC Pathology and Biomarker Committees and the JITC readership.
Access the full manuscript here.
Visit SITC’s website for more updates and educational resources on cutting-edge immunotherapy research.